Our Container Engineering Skillsets
Our team has years of experience developing primary packaging and secondary packaging for the pharmaceutical industry. From working with standard components and assemblies to designing and producing custom containers, needles, closures and packaging, our team does it all.
Container Engineering
With combination products and drug delivery devices becoming the options of choice to improve quality of care, NEUMA works with its customers and industry partners to quickly and efficiently develop custom drug container systems to allow for early feasibility evaluation (e.g. preliminary drug stability evaluations, E&L, Container Closure Integrity) and ultimately progress to market quickly and successfully. Our Container Engineering Services can offer support at any stage of a drug delivery device project ranging from initial design input to commercialization.
01
Primary Container Design & Development
Our primary container design & development capabilities include custom container design for glass forming, custom closure design (e.g. plunger stopper), container siliconization (Cross-Linked Silicone, Silicone Oil deposition), needle siliconization, closure crimping design, and process development.
Explore More 
02
Primary Container Testing
NEUMA's primary container testing capabilities include container closure integrity testing, vacuum decay testing, pressure decay testing, and dye penetration.
Explore More 
03
Secondary Packaging Design
At NEUMA, our secondary packaging design capabilities include nest & tub design for filling line integration and material selection
Explore More 
04
Secondary Packaging Testing
NEUMA offers secondary packaging testing including transportation, sterile barrier peel testing, and sterile barrier seal integrity testing.
Explore More 
05
Fill-Finish Integration
NEUMA's fill-finish integration solutions include development and scale-up of aseptic fill/stopper equipment for novel container systems, change parts design requirements and development support with filling equipment manufacturer, and machine trial support.
Explore More Meet our Container Engineering Experts
Shaun Devitt
DIRECTOR, NEUMA ENGINEERING
Markets That Benefit From Our Container Engineering Solutions
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.
The NEUMA Container Engineering Difference
NEUMA offers a forward-thinking approach to the product development lifecycle, accessing both industry-leading technologies and disruptive innovations to position products for commercial success.
Comprehensive Solutions
Our team applies Kymanox’s development toolkit of project management, development, and quality management tools that can be customized to the needs of your company and project to ensure efficient and “fit for purpose” solutions to meet your project objectives.
Turnkey Support
Our team's broad experience and integrated development approach ensure the Right First Time products for unmet patient needs in accordance with US FDA, EU EMA, and rest-of-world regulatory requirements.
Unmatched Expertise
We offer unmatched experience and knowledge across pharmaceuticals, biologics, medical devices, combination products, and "in vitro" diagnostics, so we are equipped to tackle any project in these areas. Our Development leads serve as a central hub to leverage subject matter experts from across the organization.
Read the Latest at Kymanox
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Integrating the well-respected and trusted Agilis brand and team extends Kymanox’s capabilities in human factors (HF) by adding incredible talent, the ability to conduct HF stu...
Investment Reports Interview with Stephen M. Perry, CEO and Founder of Kymanox
Kymanox CEO and Founder, Stephen M. Perry was interviewed as part of the Investment Reports article, The New Era of Life Sciences 2023, published on 17MAR23,
What were the circumstances that brought Kymanox to life and what does your present foo...
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...